|
Market Closed -
London S.E.
11:35:13 2026-10-08 EDT
|
5-day change | 1st Jan Change | ||
| 0.6250 GBX | 0.00% |
|
0.00% | +19.05% |
| 09-30 | Thalia Therapeutics Plc, H1 2026 Earnings Call, Sep 30, 2026 | |
| 09-30 | EARNINGS: Skillcast revenue rises; World Chess loss widens | AN |
| Fiscal Period: December | 2016 (GBP) | 2017 (GBP) | 2018 (GBP) | 2019 (GBP) | 2020 (GBP) | 2021 (GBP) | 2022 (GBP) | 2023 (GBP) | 2024 (GBP) | 2025 (GBP) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | - | - | 1.95K | 7.28K | 7.26K | |||||
Other Revenues, Total | - | - | - | - | - | |||||
Total Revenues | - | - | 1.95K | 7.28K | 7.26K | |||||
Gross Profit | - | - | 1.95K | 7.28K | 7.26K | |||||
Selling General & Admin Expenses, Total | 664K | 616K | 718K | 838K | 1.02M | |||||
R&D Expenses | 1.18M | 578K | 619K | 390K | 214K | |||||
Other Operating Expenses | - | - | - | - | -61.12K | |||||
Other Operating Expenses, Total | 1.84M | 1.19M | 1.34M | 1.23M | 1.17M | |||||
Operating Income | -1.84M | -1.19M | -1.34M | -1.22M | -1.17M | |||||
Interest Expense, Total | - | - | - | - | - | |||||
Interest And Investment Income | 677 | 1 | - | - | - | |||||
Net Interest Expenses | 677 | 1 | - | - | - | |||||
Other Non Operating Income (Expenses) | - | - | -89.18K | - | 80 | |||||
EBT, Excl. Unusual Items | -1.84M | -1.19M | -1.42M | -1.22M | -1.17M | |||||
Restructuring Charges | - | - | - | - | - | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | -1.84M | -1.19M | -1.42M | -1.22M | -1.17M | |||||
Income Tax Expense | -298K | -164K | -148K | -101K | 42.99K | |||||
Earnings From Continuing Operations | -1.54M | -1.03M | -1.28M | -1.12M | -1.21M | |||||
Net Income to Company | -1.54M | -1.03M | -1.28M | -1.12M | -1.21M | |||||
Minority Interest | - | - | 7.45K | 61.37K | 3.13K | |||||
Net Income - (IS) | -1.54M | -1.03M | -1.27M | -1.06M | -1.21M | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | -1.54M | -1.03M | -1.27M | -1.06M | -1.21M | |||||
Net Income to Common Excl. Extra Items | -1.54M | -1.03M | -1.27M | -1.06M | -1.21M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.01 | -0.01 | -0.01 | -0 | -0 | |||||
Basic EPS - Continuing Operations | -0.01 | -0.01 | -0.01 | -0 | -0 | |||||
Basic Weighted Average Shares Outstanding | 181M | 186M | 243M | 340M | 724M | |||||
Net EPS - Diluted | -0.01 | -0.01 | -0.01 | -0 | -0 | |||||
Diluted EPS - Continuing Operations | -0.01 | -0.01 | -0.01 | -0 | -0 | |||||
Diluted Weighted Average Shares Outstanding | 181M | 186M | 243M | 341M | 724M | |||||
Normalized Basic EPS | -0.01 | -0 | -0 | -0 | -0 | |||||
Normalized Diluted EPS | -0.01 | -0 | -0 | -0 | -0 | |||||
Supplemental Items | ||||||||||
EBITA | -1.84M | -1.19M | -1.34M | -1.22M | -1.17M | |||||
EBIT | -1.84M | -1.19M | -1.34M | -1.22M | -1.17M | |||||
Effective Tax Rate - (Ratio) | 16.19 | 13.74 | 10.38 | 8.28 | -3.69 | |||||
Current Domestic Taxes | - | - | - | - | - | |||||
Total Current Taxes | -298K | -164K | -148K | -101K | - | |||||
Normalized Net Income | -1.15M | -746K | -883K | -702K | -725K | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 664K | 616K | 718K | 838K | 1.02M | |||||
Research And Development Expense From Footnotes | 1.18M | 578K | 619K | 390K | 214K | |||||
Stock-Based Comp., Other (Total) | 16.66K | 24K | 3.43K | 7.39K | 12.84K | |||||
Total Stock-Based Compensation | 16.66K | 24K | 3.43K | 7.39K | 12.84K |
- Stock Market
- Stocks
- THAT Stock
- Financials Thalia Therapeutics Plc
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
